Cargando…

Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats

Context: Astaxanthin (ASTX) is a xanthophyll carotenoid that reduces hemostasis in hyperlipidemic organisms. Its antihemostatic mechanisms remain unclear. Objective: The effects of ASTX on coagulation, the fibrinolytic system and platelet aggregation were investigated in hyperlipidemic rats. Materia...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Zu-Yue, Shan, Wei-Guang, Wang, Shen-Feng, Hu, Meng-Mei, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130668/
https://www.ncbi.nlm.nih.gov/pubmed/27951728
http://dx.doi.org/10.1080/13880209.2016.1261905
_version_ 1783353984319225856
author Deng, Zu-Yue
Shan, Wei-Guang
Wang, Shen-Feng
Hu, Meng-Mei
Chen, Yan
author_facet Deng, Zu-Yue
Shan, Wei-Guang
Wang, Shen-Feng
Hu, Meng-Mei
Chen, Yan
author_sort Deng, Zu-Yue
collection PubMed
description Context: Astaxanthin (ASTX) is a xanthophyll carotenoid that reduces hemostasis in hyperlipidemic organisms. Its antihemostatic mechanisms remain unclear. Objective: The effects of ASTX on coagulation, the fibrinolytic system and platelet aggregation were investigated in hyperlipidemic rats. Materials and methods: Different doses of ASTX (5, 10 and 30 mg/kg/day, p.o.) were administered for four weeks to high-fat diet-induced hyperlipidemic rats. Serum lipid and lipoprotein levels were measured with an automatic biochemical analyzer. The prothrombin time (PT), activated partial thromboplastin time (APTT) and maximum platelet aggregation rate (MAR) were determined by a coagulation analyzer. The activities of the tissue-type plasminogen activator (t-PA), type-1 plasminogen activator inhibitor (PAI-1) and endothelial nitric oxide synthase (eNOS), as well as the levels of thromboxane B(2) [TXB(2)], 6-keto prostaglandin F(1α) [6-keto-PGF(1α)] and platelet granule membrane protein (GMP-140), were measured with enzyme-linked immunosorbent assay kits. Gene and protein expression levels were analyzed by reverse transcriptase polymerase chain reaction and Western blot, respectively. Results: ASTX (30 mg/kg) treatment in hyperlipidemic rats reduced serum TG (0.58 ± 0.14 versus 1.12 ± 0.24 mmol/L), serum TC (1.77 ± 0.22 versus 2.24 ± 0.21 mmol/L), serum LDL-C (1.13 ± 0.32 versus 2.04 ± 0.48 mmol/L), serum MDA (69%), plasma MAR (55%), serum TXB2/6-keto-PGF1α (34%) and serum GMP-140 levels (25%), plasma PAI-1 activity (48%) and downregulated the mRNA (33%) and protein (23%) expression of aorta eNOS, the mRNA (79%) and protein (72%) expression levels of aorta PAI-1. However, ASTX (30 mg/kg/d) treatment increased serum SOD activity (2.1 fold), serum GPx activity (1.8 fold), plasma PT (1.3 fold), plasma APTT (1.7 fold), serum NO (1.4-fold), serum 6-keto-PGF1α (1.3 fold). Conclusions: ASTX reduced blood coagulation and platelet aggregation and promoted fibrinolytic activity in hyperlipidemic rats. These activities were closely correlated with ASTX, maintaining the balance of t-PA/PAI-1, NO/ROS and TXA2/PGI2 in vivo.
format Online
Article
Text
id pubmed-6130668
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61306682018-09-27 Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats Deng, Zu-Yue Shan, Wei-Guang Wang, Shen-Feng Hu, Meng-Mei Chen, Yan Pharm Biol Research Article Context: Astaxanthin (ASTX) is a xanthophyll carotenoid that reduces hemostasis in hyperlipidemic organisms. Its antihemostatic mechanisms remain unclear. Objective: The effects of ASTX on coagulation, the fibrinolytic system and platelet aggregation were investigated in hyperlipidemic rats. Materials and methods: Different doses of ASTX (5, 10 and 30 mg/kg/day, p.o.) were administered for four weeks to high-fat diet-induced hyperlipidemic rats. Serum lipid and lipoprotein levels were measured with an automatic biochemical analyzer. The prothrombin time (PT), activated partial thromboplastin time (APTT) and maximum platelet aggregation rate (MAR) were determined by a coagulation analyzer. The activities of the tissue-type plasminogen activator (t-PA), type-1 plasminogen activator inhibitor (PAI-1) and endothelial nitric oxide synthase (eNOS), as well as the levels of thromboxane B(2) [TXB(2)], 6-keto prostaglandin F(1α) [6-keto-PGF(1α)] and platelet granule membrane protein (GMP-140), were measured with enzyme-linked immunosorbent assay kits. Gene and protein expression levels were analyzed by reverse transcriptase polymerase chain reaction and Western blot, respectively. Results: ASTX (30 mg/kg) treatment in hyperlipidemic rats reduced serum TG (0.58 ± 0.14 versus 1.12 ± 0.24 mmol/L), serum TC (1.77 ± 0.22 versus 2.24 ± 0.21 mmol/L), serum LDL-C (1.13 ± 0.32 versus 2.04 ± 0.48 mmol/L), serum MDA (69%), plasma MAR (55%), serum TXB2/6-keto-PGF1α (34%) and serum GMP-140 levels (25%), plasma PAI-1 activity (48%) and downregulated the mRNA (33%) and protein (23%) expression of aorta eNOS, the mRNA (79%) and protein (72%) expression levels of aorta PAI-1. However, ASTX (30 mg/kg/d) treatment increased serum SOD activity (2.1 fold), serum GPx activity (1.8 fold), plasma PT (1.3 fold), plasma APTT (1.7 fold), serum NO (1.4-fold), serum 6-keto-PGF1α (1.3 fold). Conclusions: ASTX reduced blood coagulation and platelet aggregation and promoted fibrinolytic activity in hyperlipidemic rats. These activities were closely correlated with ASTX, maintaining the balance of t-PA/PAI-1, NO/ROS and TXA2/PGI2 in vivo. Taylor & Francis 2016-12-12 /pmc/articles/PMC6130668/ /pubmed/27951728 http://dx.doi.org/10.1080/13880209.2016.1261905 Text en © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Deng, Zu-Yue
Shan, Wei-Guang
Wang, Shen-Feng
Hu, Meng-Mei
Chen, Yan
Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title_full Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title_fullStr Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title_full_unstemmed Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title_short Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
title_sort effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130668/
https://www.ncbi.nlm.nih.gov/pubmed/27951728
http://dx.doi.org/10.1080/13880209.2016.1261905
work_keys_str_mv AT dengzuyue effectsofastaxanthinonbloodcoagulationfibrinolysisandplateletaggregationinhyperlipidemicrats
AT shanweiguang effectsofastaxanthinonbloodcoagulationfibrinolysisandplateletaggregationinhyperlipidemicrats
AT wangshenfeng effectsofastaxanthinonbloodcoagulationfibrinolysisandplateletaggregationinhyperlipidemicrats
AT humengmei effectsofastaxanthinonbloodcoagulationfibrinolysisandplateletaggregationinhyperlipidemicrats
AT chenyan effectsofastaxanthinonbloodcoagulationfibrinolysisandplateletaggregationinhyperlipidemicrats